Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
Type
Guidance (294)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (5)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 191 to 200 of 325
Guidance and quality standards awaiting development
Title
Type
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
Technology appraisal guidance
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over TSID 12047
Technology appraisal guidance
Pelvic floor dysfunction
Quality standard
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021
Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Technology appraisal guidance
Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068
Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953
Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399
Technology appraisal guidance
Previous page
1
…
18
19
Current page
20
21
22
…
33
Page
20
of
33
Next page
Results per page
10
25
50
All
Back to top